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 11 
Abstract 12 
 13 
β-Lactamase-mediated resistance is a growing threat to the continued use of β-lactam 14 
antibiotics. The use of the β-lactam-based serine-β-lactamase (SBL) inhibitors clavulanic 15 
acid, sulbactam, tazobactam, and, more recently, the non-β-lactam inhibitor avibactam has 16 
extended the utility of β-lactams against bacterial infections demonstrating resistance via 17 
these enzymes. These molecules are, however, ineffective against the metallo-β-lactamases 18 
(MBLs), which catalyse their hydrolysis. To date, there are no clinically available metallo-β-19 
lactamase inhibitors. Co-production of MBLs and SBLs in resistant infections is, thus, of 20 
major clinical concern. The development of ‘dual-action’ inhibitors, targeting both SBLs and 21 
MBLs, is of interest, but these are considered difficult to achieve due to the structural and 22 
mechanistic differences between the two enzyme classes. We recently reported evidence 23 
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that cyclic boronates can inhibit both serine- and metallo-β-lactmases. Here we report that 24 
cyclic boronates are able to inhibit all four classes of β-lactamase, including the class A 25 
extended spectrum β-lactamase, CTX-M-15, the class C enzyme, AmpC from Pseudomonas 26 
aeruginosa, and class D OXA enzymes with carbapenem-hydrolysing capabilities. We 27 
demonstrate that cyclic boronates can potentiate the use of β-lactams against Gram-28 
negative clinical isolates expressing a variety of β-lactamases. Comparison of a crystal 29 
structure of a CTX-M-15:cyclic boronate complex with structures of cyclic boronates 30 
complexed with other β-lactamases reveals remarkable conservation of the small molecule 31 
binding mode, supporting our proposal that these molecules work by mimicking the 32 
common tetrahedral anionic intermediate present in both serine- and metallo-β-lactamase 33 
catalysis.  34 
 35 
Introduction 36 
 37 
The β-lactam antibiotics remain the most important drug class for the treatment of bacterial 38 
infections (1). However, their continued use is jeopardized by the increasing spread of 39 
resistance mechanisms, including that mediated by β-lactamases, which, cumulatively, can 40 
hydrolyse all classes of β-lactam antibiotics (2). β-Lactamases can be divided into four 41 
classes (Ambler classes A, B, C and D (3)) and manifest considerable sequence and structural 42 
diversity as well as different, but overlapping, substrate profiles (4). The serine-β-lactamases 43 
(SBLs), classes A, C and D, likely evolved from the penicillin-binding protein (PBP) targets of 44 
β-lactam antibiotics (5-8). Among the SBLs the extended-spectrum SBLs (ESBLs) are of 45 
particular clinical concern. Their ability to hydrolyse extended spectrum cephalosporins and 46 
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the monobactam, aztreonam (9),  is an important reason for failure of cephalosporin-based 47 
therapies (10). Of particular note are the CTX-M enzymes, which have become the most 48 
prevalent ESBLs worldwide (11). The SBL carbapenemases, such as variants of class D 49 
enzymes OXA-23 and OXA-48, are a growing concern, since they are able to hydrolyse 50 
carbapenems, which have often been used as the last line of antibacterial defence (12). 51 
Inhibitors of the SBLs include the β-lactams clavulanic acid, sulbactam and tazobactam, 52 
which are active against class A β-lactamases (2, 13, 14), and the recently introduced non-β-53 
lactam β-lactamase inhibitor, avibactam, which has a broader spectrum of SBL inhibition 54 
activity (15, 16). These inhibitors have increased the efficacy of β-lactam antibiotics against 55 
SBL-mediated resistance in bacteria, but they are inactive against the Zn(II)-dependent class 56 
B metallo-β-lactamases (MBLs), which constitute a structural and mechanistically distinct 57 
family of enzymes and exhibit considerable heterogeneity, even amongst themselves (17). 58 
The MBLs are able to hydrolyse all classes of β-lactam except for monobactams (18). The 59 
ability of the MBLs to hydrolyse SBL inhibitors, including avibactam (19), is a growing 60 
problem in the treatment of infections where both SBL- and MBL-mediated cephalosporin 61 
and carbapenem resistance have been acquired (20). To date there are no clinically 62 
approved MBL inhibitors. 63 
As a consequence of increasing variation in the β-lactamase-mediated resistance to 64 
β-lactam antibiotics, the development of broad-spectrum inhibitors of both the SBLs and 65 
MBLs is of considerable interest. This is presently perceived to be challenging due to the 66 
mechanistic and structural differences between the SBLs and MBLs. We have recently 67 
reported that cyclic boronates can inhibit representatives of  class A, B, and D β-lactamases 68 
(21). Cyclic boronates act as analogues of the first tetrahedral intermediate that is common 69 
to both SBLs and MBLs. Here we show that cyclic boronates are able to inhibit all classes of 70 
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β-lactamase, including the class A ESBL, CTX-M-15, the class C enzyme, AmpC from 71 
Pseudomonas aeruginosa, and two carbapenem-hydrolysing OXA variants, OXA-23 and OXA-72 
48. These cyclic boronates are effective in inhibiting the growth of clinical Gram-negative 73 
bacterial strains expressing multiple β-lactamases. Crystallographic analysis of a cyclic 74 
boronate complexed with CTX-M-15 supports the proposal that the cyclic boronates closely 75 
mimic the first tetrahedral intermediate in bicyclic β-lactam hydrolysis. 76 
 77 
Materials and Methods 78 
 79 
Cloning 80 
Serine β-lactamases were amplified by direct PCR from producer bacterial strains and 81 
expressed as N-terminal hexahistidine fusions from the T7 vector pOPINF (22). CTX-M-15 82 
was amplified from E. coli strain EO516 (kind gift of Prof. Neil Woodford, Public Health 83 
England) (23); P. aeruginosa AmpC was amplified from strain PAO1 (kind gift of the former 84 
Pseudomonas genetic stock center, East Carolina University) (24); OXA-23 and OXA-48 were 85 
amplified from clinical Acinetobacter baumannii and Klebsiella pneumoniae isolates (kind 86 
gifts of Prof. Timothy Walsh and Dr. Mark Toleman, Cardiff University). β-lactamase open 87 
reading frames encoding the mature polypeptides (i.e with regions encoding the signal 88 
peptide removed) were amplified by PCR using Phusion polymerase (New England Biolabs) 89 
and primers as detailed in Supplementary Table S1. PCR products were cloned into the 90 
pOPINF T7 expression vector (22), linearized at the KpnI and HindIII sites, using the InFusion 91 
recombinase system (Clontech) (25), transformed into E. coli Stellar (Clontech) and positive 92 
clones selected by blue-white screening. Recombinant plasmids were purified and 93 
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sequenced (Eurofins Genomics) to confirm identity with published sequences and that no 94 
mutations had been introduced during the cloning procedure. The resulting expression 95 
constructs encode (exclusive of vector derived amino acid residues) mature β-lactamase 96 
sequences starting at residues 29 (CTX-M-15), 27 (AmpC), 18 (OXA-23) and 22 (OXA-48). 97 
 98 
Enzyme production 99 
Recombinant CTX-M-15, AmpC, OXA-23 and OXA-48, each with an N-terminal His-tag, were 100 
produced in E. coli BL21(DE3) cells using auto-induction medium supplemented with 50 μg 101 
mL-1 ampicillin. Cells were grown for four hours at 37 °C before cooling to 18 °C and 102 
continuing growth overnight. Cells were harvested by centrifugation (10 min, 10000 g), 103 
resuspended in 50 mL lysis buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 5 mM imidazole), 104 
supplemented with DNAse I, and lysed by sonication. The supernatant was loaded onto a 5 105 
mL HisTrap HP column followed by extensive washing with 50 mM HEPES, pH 7.5, 500 mM 106 
NaCl, 5 mM imidazole before elution with a 20−500 mM imidazole gradient. FracƟons 107 
containing purified enzyme were concentrated by centrifugal ultrafiltration (Amicon Ultra -108 
15 mL, 10 kDa MWCO, Millipore). The resultant solution was injected onto a Superdex S200 109 
column (300 mL) and eluted with 50 mM HEPES, pH 7.5, 200 mM NaCl. Fractions containing 110 
pure His-tagged enzyme were incubated overnight at 4 °C with His-tagged 3C protease 111 
(1:100 w/w) to remove the N-terminal His-tag. The 3C protease together with any uncleaved 112 
protein the digestion mixture was removed by use of a second HisTrap HP column pre-113 
equilibrated with 50 mM HEPES, pH 7.5, 500 mM NaCl, 20 mM imidazole. Purified enzyme 114 
fractions as identified by SDS-PAGE, were pooled and concentrated by centrifugal 115 
ultrafiltration before buffer exchange into 25 mM HEPES, pH 7.5, 100 mM NaCl. The 116 
concentrations of the purified proteins were determined using a NanoDrop ND-1000 117 
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spectrophotometer (Thermo Scientific, ε = 25440, 61310, 43430 or 63940 M-1 cm-1 for CTX-118 
M-15, AmpC, OXA-23 and OXA-48, respectively). 119 
Recombinant TEM-1 (26) with an N-terminal His-tag, VIM-1 (27) with a 3C-cleaved C-120 
terminal His-tag, and OXA-10 (28) were produced as previously described. The 121 
concentrations of the purified proteins were determined using a NanoDrop ND-1000 122 
spectrophotometer. Thermo Scientific, (ε = 27960, 29910, or 48930 M-1 cm-1 for TEM-1, 123 
VIM-1, and OXA-10, respectively) 124 
 125 
13C-Labelling of OXA-10 Enzyme 126 
The 13C labelling of carbamylated lysine was based on a literature protocol (29). Purified 127 
OXA-10 enzyme was first dialyzed overnight against degassed 25 mM sodium acetate, pH 128 
4.5, 0.1 mM EDTA, then overnight against 50 mM sodium phosphate, pH 7.4, 0.1 mM EDTA, 129 
1 mM NaH13CO3 (Sigma-Aldrich). The enzyme was then dialyzed overnight against 50 mM 130 
sodium phosphate, pH 7.4, 0.1 mM EDTA, 10 mM NaH13CO3, aliquoted, and frozen using 131 
liquid N2. 132 
 133 
Inhibition assays 134 
Inhibition assays were carried out using FC5 as a fluorogenic reporter substrate (30). 135 
Enzyme concentrations and buffers were the same as those employed in steady-state 136 
kinetic studies (Table S2). TEM-1, BcII and VIM-1 were screened at 1 nM, 500 pM and 125 137 
pM, respectively. The concentration of FC5 employed was 10 μM for TEM-1 and 5 μM for all 138 
other enzymes. IC50 values were determined by pre-incubating the enzyme with the 139 
inhibitor in the assay buffer at room temperature for 10, 30, 60 or 300 minutes prior to the 140 
addition of substrate. Data at 0 minutes incubation were obtained by addition of enzyme 141 
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into a pre-mixed solution of inhibitor and substrate. Residual enzyme activity was 142 
determined for a range of inhibitor concentrations. Non-linear regression fitting of IC50 143 
curves was carried out using a three-parameter dose-response curve in GraphPad Prism. 144 
Errors in IC50 are expressed as: ఙ (୪୭୥ ூ஼ఱబ)୪୭୥ ூ஼ఱబ × ܫܥହ଴. 145 
 146 
Antimicrobial Susceptibility Testing 147 
The in vitro activity of 2 was assessed using nine clinical isolates carrying multiple β-148 
lactamases (Table 3). Isolates selected included Enterobacteriaceae (E. coli ST 131, Klebsiella 149 
pneumoniae ST 258, Providencia stuartii) producing class A  ESBLs (CTX-M-15, CTX-M-27, 150 
SHV-5, VEB-1), serine (KPC-2) and metallo-carbapenemases (VIM-1, VIM-2), plasmid 151 
mediated AmpC (CMY-2) and/or carbapenem-hydrolysing OXA-48-like oxacillinases (OXA-152 
181, OXA-232) in various combinations. The activity against carbapenemase producing 153 
strains of Pseudomonas aeruginosa (VIM-2) and Acinetobacter baumannii (OXA-23) was also 154 
investigated. All isolates have previously undergone extensive phenotypic and genotypic 155 
characterisation (31). 156 
Bacterial susceptibility to β-lactams and standard β-lactam inhibitor (clavulanic acid 157 
(CLAV), sulbactam (SUL), and tazobactam (TAZ)) combinations was determined by broth 158 
microtitre dilution (BMD) according to the Clinical Laboratory Standards Institute (CLSI) 159 
methodology (32).  MICs were determined using commercial Sensititre GN4F panels 160 
(Thermo Scientific, UK, LOT B55051) and Mueller-Hinton II cation adjusted broth (Oxoid, 161 
UK), with and without the addition of 2 at a fixed concentration of 10 µg/ml. Plates were 162 
incubated at 37 °C for 18 hrs and MICs read by eye following the addition of Alamar Blue 163 
reagent (Trek Diagnostics). 164 
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The inhibitory effects of 2 on susceptibility to 19 diverse β-lactam compounds was 165 
also assessed in Kirby-Bauer disc diffusion tests. Combination discs (Oxoid) were prepared 166 
with a fixed ratio of 2:1 between the β-lactam (µg) and 2. Zones of inhibition were 167 
compared around combined and un-supplemented discs following overnight incubation on 168 
MH II plates. 169 
 170 
NMR Spectroscopy 171 
13C NMR experiments used a Bruker AVIII 600 MHz spectrometer equipped with a Prodigy 172 
broadband cryoprobe. Spectra were acquired at 298 K using a standard Bruker 13C pulse 173 
sequence. The experimental parameters used were: 2048 scans, 36058 Hz spectral width, 174 
2.0 s relaxation delay, and 65536 data points. A line broadening of 10 Hz was applied to all 175 
spectra. NMR samples contained 560 μM OXA-10 and 10 mM NaH13CO3, and were 176 
supplemented with 10% D2O. The impact of boronate 1 was tested at a concentration of 5 177 
mM. 178 
 179 
Crystallisation, X-ray data collection and processing 180 
Crystallisation experiments were set up using a 13 mg mL-1 solution of CTX-M-15 in 50 mM 181 
HEPES, pH 7.5, 100 mM NaCl supplemented with 10 mM 1. Crystallisation was performed at 182 
room temperature using sitting drop vapour diffusion methods. Crystals were obtained after 183 
two days using 100 μL of 100 mM HEPES, pH 7.5, 70% 2,4-methylpentanediol in the 184 
reservoir and a 1:2 mixture (1 μL:2 μL) of protein to reservoir solution in the crystallisation 185 
drop. Crystals were cryo-protected using 25% glycerol in reservoir solution before 186 
harvesting with nylon loops and flash-cooling in liquid nitrogen. Diffraction data were 187 
collected at 100 K using a Rigaku FRE+ Superbright diffractometer. Diffraction data were 188 
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integrated and scaled using HKL3000 (33). The structure was solved by molecular 189 
replacement with Phaser (34) using a published structure (PDB accession code: 4HBT(35)) as 190 
a search model. The structure was then fit and refined iteratively using PHENIX and Coot 191 
(36, 37). 192 
 193 
Structural energy minimisation 194 
Energy minimisation of small molecule structures was performed using the MM2 energy 195 
minimisation function in ChemBio3D Ultra (38). 196 
 197 
Results 198 
 199 
Cyclic boronate inhibition of serine-β-lactamases and metallo-β-lactamases 200 
To investigate the extent to which cyclic boronates inhibit class C β-lactamases as well as 201 
the important class A ESBL and class D carbapenemase targets, we used a fluorogenic assay 202 
(30) to screen the cyclic boronates, which we have found to inhibit other β-lactamases (21), 203 
against them.  The β-lactamases used for screening included TEM-1, CTX-M-15 (class A), the 204 
MBL from Bacillus cereus, BcII, Verona integron-encoded metallo-β-lactamase 1, VIM-1 205 
(class B), AmpC from Pseudomonas aeruginosa (class C), OXA-23 and OXA-48 (class D), 206 
collectively representing all classes of β-lactamase. (For comparison with other relevant 207 
publications, we also screened CTX-M-15, AmpC, OXA-23, and OXA-48 with the commonly 208 
used reporter substrate nitrocefin (39), Table S2). To benchmark the potency of the cyclic 209 
boronates we also screened the clinically used SBL inhibitors avibactam (MedChemexpress 210 
LLC) (16, 40), sulbactam (41, 42), and BLI-489, a potent inhibitor of class D enzymes (2, 43, 211 
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44). For MBLs we used the broad-spectrum thiol-based MBL inhibitors L-captopril (45, 46) 212 
and (racemic) thiomandelic acid (47, 48) (Tables 1 & 2, see Figure S1 for structures of the 213 
inhibitors). Since variations in the rate of reaction with, at least, avibactam has been 214 
reported among the SBLs (16), we also investigated the time courses of  inhibition by these 215 
compounds over six hours. 216 
Both cyclic boronates 1 and 2 exhibit inhibition against all five of the SBLs tested with 217 
IC50 values ranging from 250 to 2 nM (Table 1). 1 and 2 exhibit a similar inhibition potency 218 
against TEM-1 and CTX-M-15, 2 shows around 10-fold lower IC50 values than 1 against AmpC 219 
(9.8 ± 0.3 nM vs 120 ± 10 nM, respectively, with 10 minutes pre-incubation) while 1 exhibits 220 
10- to 15-fold lower IC50s than 2 against the OXA enzymes (250 ± 1 nM vs 2600 ± 100 nM 221 
after 10 minutes incubation for OXA-23 and 160 ± 1 nM vs 2600 ± 200 nM after 10 minutes 222 
incubation for OXA-48). Against TEM-1 and CTX-M-15, 1 and 2 show similar potency to 223 
avibactam and BLI-489, with IC50 values of low nanomolar to sub-nanomolar levels. Against 224 
AmpC, 2 shows a similar potency to avibactam while 1 exhibits up to 60-fold lower IC50 225 
values than avibactam (9.8 ± 0.3 nM and 190 ± 10 nM at 10 minutes, respectively) with 226 
results comparable to those for BLI-489 (30 ± 1 nM at 10 minutes). Neither 1 nor 2 were 227 
able to achieve potency comparable with the lowest IC50 values exhibited by avibactam and 228 
BLI-489 against the OXA enzymes, with IC50 values for 1 being around 10 to 20-fold higher 229 
and those for 2 being around 100 to 200-fold higher .  230 
The time-dependency of inhibition was found to vary depending on the particular 231 
inhibitor-enzyme combination examined (Table 1). Where substantial time dependency in 232 
the inhibition was observed, the largest decrease in IC50 generally manifested over the first 233 
10 minutes of inhibition. Avibactam showed time-dependency in its inhibition of all the 234 
tested SBLs with the lowest IC50 value typically achieved after 60 or 360 minutes pre-235 
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incubation. The IC50 values obtained with BLI-489 only showed substantial time-dependency 236 
with CTX-M-15 and AmpC, with the lowest IC50 values seen after longer incubation times, as 237 
seen with avibactam. The time-dependency of inhibition by the cyclic boronates was similar 238 
to that observed for BLI-489 (i.e. seen with CTX-M-15 and AmpC but not with TEM-1 or the 239 
OXA enzymes) (Table 1). For CTX-M-15, a significant increase in the IC50 values for avibactam 240 
and BLI-489 was observed between 60 and 360 minutes of incubation. This may be the 241 
result of slow hydrolysis of the inhibited acyl-enzyme to restore a small population of active 242 
enzyme. 243 
We also screened the cyclic boronates against the model MBL, BcII, and VIM-1 using 244 
the FC5-based fluorogenic assay (30). In all cases the inhibition of the MBLs by 2 was around 245 
10 times more potent than by 1 (Table 2). 1 exhibited IC50 values around two- to five-fold 246 
lower than those seen with L-captopril. 2 showed very similar potency to thiomandelic acid 247 
against BcII but showed five to 10-fold greater potency than thiomandelic acid against VIM-248 
1. No time-dependency of MBL inhibition by either the cyclic boronates or thiol-based 249 
inhibitors was observed (Table 2). 250 
 251 
Susceptibility of clinical isolates to cyclic boronate 2 252 
Consistent with our previous work (21), 2 was observed to be the more potent inhibitor of 253 
the isolated MBLs, compared to 1. Since potency against different types of MBL is a highly 254 
desirable characteristic in the design of MBL/SBL dual inhibitors, 2 (10 µg/mL) was thus 255 
tested in combination with a number of β-lactams against a variety of Gram-negative clinical 256 
isolates known to produce multiple β-lactamases. Susceptibility to the monobactams 257 
aztreonam (AZT) and cephalosporins (ceftriaxone (CRO), ceftazidime (CAZ), and cefepime 258 
(FEP)) was either increased or completely restored to strains producing CTX-M-1-like (CTX-259 
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M-15, CTX-M-27) enzymes. MICs to ampicillin (AMP) and piperacillin (PIP) in combination 260 
with fixed ratios of clavulanic acid (CLAV), sulbactam (SUL), and tazobactam (TAZ) were also 261 
lower for CTX-M containing isolates but not significantly in those also producing an OXA 262 
(OXA-1, OXA-181, OXA-23) or plasmid-borne AmpC (CMY-4) enzyme. For Enterobacteriaceae 263 
producing MBLs, heightened activity was seen with carbapenems against VIM-4 producing 264 
K. pneumoniae and VIM-1 producing P. stuartii. There were less marked effects on 265 
cephalosporin MICs, presumably due to co-production of SHV and VEB-like ESBLs and hyper-266 
expression of chromosomal AmpC in these isolates. In strains with OXA-like carbapenem-267 
hydrolysing class D β-lactamases (CHDLs), carbapenem susceptibility was increased in E. coli 268 
producing the OXA-181 variant, in combination with CTX-M-15 and CMY-4, but not against a 269 
multi-drug resistant K. pneumoniae producing the OXA-232 variant in association with CTX-270 
M-15 and multiple other class SHV ESBLs. Of note, no significant effects of 2 were seen on 271 
the carbapenem susceptibility of either VIM-2 producing P. aeruginosa or A. baumannii with 272 
OXA-23 (Table 3) 273 
Disc diffusion screens in which 2 was added in a fixed ratio against the same strains 274 
revealed some interesting findings on its potential as an inhibitor (Supplemental Disc 275 
Diffusion Test Images). In Enterobacteriacae, 2 generally enhanced the activity of PIP, AZT, 276 
cefoxitin (FOX), cefotaxime (CTX) and CAZ in those without OXA-CHDLs. The effects on 277 
carbapenems were clearly observed for the VIM-4 producing strains at the 2:1 ratio.  278 
 279 
13C NMR study with OXA-10 280 
For the class D OXA enzymes, the active site lysine (Lys70) is carbamylated via non-281 
enzymatic reaction with carbon dioxide (49). This residue is critical for the activity of the 282 
enzymes and acts as a general acid/base during β-lactam hydrolysis (29). Since the 283 
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carbamylation of Lys70 is reversible, it is possible to site-specifically label the residue with 284 
13C, via incubation with a 13C bicarbonate buffer. This labelling allows for changes of the 285 
active site, for example inhibitor binding, to be studied using NMR (29). Using this reported 286 
technique, we labelled the carbamylated Lys70 of OXA-10 with 13C (using NaH13CO3) in order 287 
to monitor binding of the cyclic boronate 1 within the active site of the enzyme (Figure S6).  288 
Upon binding of the inhibitor, a 6 ppm shift in the 13C-labelled carbamylate signal is 289 
observed.  290 
 291 
Crystal structure of 2 bound to CTX-M-15 292 
Crystal structures of the cyclic boronates 1 and 2 in complex with class B and D β-lactamases 293 
(BcII and VIM-2, and OXA-10, respectively) and PBP-5 from E. coli have been reported (21); 294 
however, structural information on inhibition of the clinically important class A β-295 
lactamases, in particular ESBLs, by cyclic boronates has not been described. We thus worked 296 
to obtain a structure of the ESBL CTX-M-15:1 complex, which diffracted to 1.95 Å resolution 297 
(See Table S4 for crystallographic data). The structure was solved by molecular replacement 298 
using the reported structure of the apo-enzyme (PDB accession code: 4HBT (35)) as a search 299 
model. The overall structure of the CTX-M-15:1 complex is highly similar to that of the 300 
search model with an RMSD of 0.194 Å over Cα atoms. In a similar fashion to that seen in a 301 
CTX-M-15:Avibactam complex crystal structure (PDB accession code: 4S2I (50)), comparison 302 
with the apo-enzyme reveals no remarkable changes in the positions of the backbone or 303 
amino acid side chains upon reaction with cyclic boronate 1. 304 
Analysis of the electron density maps clearly reveals 1 as bound at the active site via 305 
reaction with the side chain of Ser73 (Figure 2A). In an analogous manner to the structures 306 
of OXA-10 and PBP-5 with 2 (21), PDB accession codes 5FQ9 and 5J8X, respectively, the 307 
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electron density map provides clear evidence for tetrahedral coordination of the boron 308 
atom (Figure S7).  Aside from the covalent reaction with Ser73, 1 is positioned to form 309 
hydrogen bonding interactions with the side chains of Lys76, Asn107, Ser133, Asn135, 310 
Thr238 and Ser240 as well as backbone atoms of Ser73, and Ser240 and three nearby water 311 
molecules, Waters 4, and 116. In addition there is a hydrophobic/aromatic interaction 312 
between the sidechain of Tyr108 and the planar aromatic ring of the ligand. Interestingly, 313 
and as seen in the CTX-M-15:avibactam complex (50), a water molecule is observed in the 314 
CTX-M-15:1 complex which occupies the same position as the water responsible for 315 
hydrolysis of the acyl-enzyme intermediate in CTX-M-15-catalysed β-lactam hydrolysis, 316 
Wat4 in Figures 2 and S6 (35). 317 
We then compared the conformation of the cyclic boronate 1 in CTX-M-15 with 318 
those observed in MBLs (BcII, PDB accession code: 5FQB, and VIM-2, PDB accession code: 319 
5FQC), and OXA-10 (PDB accession code: 5FQ9) as well as PBP-5 (PDB accession code: 5J8X). 320 
Although there are some variations in the precise orientations of the C-7 cyclohexyl 321 
amide/aromatic acetamide side chain, the conformation of the fused bicyclic boronate ring 322 
system is remarkably well conserved across all the structures analysed (Figure 2C). In 323 
support of the proposal that the cyclic boronates mimic the first tetrahedral intermediate in 324 
β-lactam hydrolysis, which is common in both SBL and MBL catalysis, small molecule energy 325 
minimisation studies on 2 and the tetrahedral species produced by addition of a hydroxide 326 
ion onto the β-lactam carbonyl of cefalexin, reveal strong structural similarity between the 327 
two species. 328 
 329 
 330 
 331 
 o
n
 February 24, 2017 by St Bartholom
ew's & the Royal
http://aac.asm
.org/
D
ow
nloaded from
 
15 
 
Discussion 332 
 333 
The results reveal that cyclic boronates 1 and 2, which are based on β-lactamase inhibitors 334 
described in patent literature (51), are able to inhibit all classes of β-lactamase, including 335 
the important clinically relevant ESBL CTX-M-15 and the OXA carbapenemases, as well as 336 
AmpC from P. aeruginosa, with low micromolar to low nanomolar IC50 ranges (Tables 1 & 2). 337 
The compounds show similar inhibition potency to avibactam against TEM-1, CTX-M-15 and 338 
AmpC. 1 was the more potent of the two cyclic boronates against the OXA enzymes, but was 339 
unable to achieve the potency of avibactam against these enzymes (16). However, the fact 340 
that the described cyclic boronate scaffold has yet to be optimised suggests that greater 341 
potency should be possible for cyclic boronates against the class D β-lactamases, in line with 342 
that seen for other classes. Interestingly, NMR data acquired with OXA-10 show that 343 
carbamylation of the active site lysine is maintained upon binding of boronate 1 (Figure S6). 344 
The observed shift  of 6 ppm is substantial when compared to that observed upon binding of 345 
hydroxyisopropylpenicillanates, where a shift of 0 to 0.4 ppm is observed (52). The greater 346 
shift of the 13C signal on binding of the boronate likely reflects the different environment of 347 
the active site serine – being bound to an sp3 anionic boron centre when complexed to 1 as 348 
opposed to an sp2 carbon centre in the hydroxyisopropylpenicillanate complex.  349 
Time courses of inhibition against the SBLs reveal that time-dependence in IC50 value 350 
is manifest, the magnitude of which is dependent on the enzyme-inhibitor combination 351 
employed. This observation is consistent with potential variations in acylation rates seen 352 
with avibactam (16) and the SBLs as well as ‘on-enzyme’ fragmentation/cross-linking 353 
reactions that can occur subsequent to acylation, as demonstrated, for example, in the case 354 
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of sulbactam (41, 42) and BLI-489 (53). Notably TEM-1 and CTX-M-15 appear to manifest 355 
differences in the time-dependency of their inhibition by all five of the tested inhibitors, as 356 
has been previously demonstrated for the response of TEM-1 and CTX-M-9 to clavulanic 357 
acid, sulbactam and tazobactam (54), emphasising the variation in the properties of the β-358 
lactamases even within the same class (5). 359 
1 and 2 exhibit sub-micromolar IC50s against the MBLs, BcII and VIM-1 with 2 being 360 
the more potent compound against both enzymes. Inhibition of BcII by 2 is comparable in 361 
potency to thiomandelic acid, while 2 is around 10 times more potent than thiomandelic 362 
acid against VIM-1. Avibactam is a potent inhibitor of SBLs but, notably, is hydrolysed slowly 363 
by some MBLs (19, 55). Time courses of cyclic boronate inhibition against the enzymes 364 
tested demonstrated no time-dependence for inhibition of the MBLs, at least under our 365 
experimental conditions. Despite avibactam being a potent inhibitor of SBLs, it is able to be 366 
hydrolysed by MBLs (19), suggesting potential problems in the long-term clinical use of 367 
avibactam (and other inhibitors working by acylation) as resistance mediated by 368 
combinations of SBLs and MBLs become more prevalent (20). In contrast, no β-lactamase-369 
catalysed turnover of the cyclic boronates has been seen (as expected) and, to date, we 370 
have no evidence for these compounds binding to β-lactamases or PBPs in a ring-opened 371 
fashion. This is consistent with a recent publication suggesting that, at least for 6-membered 372 
boronate rings, the closed form is the dominant species in solution (56). 373 
Cyclic boronate 2 potentiated the activity of all four classes of β-lactam against 374 
Gram-negative clinical isolates (Table 3). Co-administration of 2 alongside clinically used SBL 375 
inhibitors clavulanic acid, sulbactam and tazobactam was able to further potentiate the 376 
activity of penicillins against some E. coli strains (EC107 and EC113) when compared to co-377 
administration with the SBL inhibitors alone. 2 also increased the effectiveness of both 378 
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cephalosporins and carbapenems against VIM-producing K. pneumoniae strains, although 379 
this result is not apparent with KP41 – possibly due to the sheer number of β-lactamases 380 
(six) being produced. Activity against the VIM-2-producing P. aeruginosa was also limited. 381 
Mechanisms of multi-drug resistance in this strain have not yet been fully elucidated, 382 
although production of the native AmpC β-lactamase combined with upregulated efflux and 383 
permeability lesions are likely to be involved. An increased susceptibility to ceftolozane was 384 
a common finding regardless of the number or class of β-lactamase produced, except in A. 385 
baumannii. Ceftolozane is a 5th generation cephalosporin, recently developed for use in 386 
combination with tazobactam (57). The limited isolate results presented here suggest that 387 
ceftolozane, partnered with a cyclic boronate, could be an attractive β-lactam/inhibitor 388 
combination to pursue in future. 389 
A structure of the CTX-M-15:1 complex reveals a conserved mode of binding for this 390 
inhibitor, very similar to our previously reported structures, with a tetrahedral boron centre 391 
and the closed bicyclic scaffold maintained as in our previously reported work (21). 392 
Comparison of our structure with that of CTX-M-15 in complex with RPX-7009, a boron-393 
based SBL inhibitor currently in phase III clinical trials (58, 59), and a TEM-1:BJH (60) 394 
complex reveals a striking similarity in the mode of binding for these related scaffolds 395 
(Figure S8). Interestingly, the latter structure was interpreted as an acyclic boronate binding 396 
mode, despite the compound being able to adopt a near identical bicyclic conformation to 397 
our inhibitors via reaction of its phenolic oxygen with the boron centre (Figure S8C) (60). It 398 
should be noted that, in contrast to the structural conservation observed for the cyclic 399 
boronate complex conformations, there is considerably more variation in the structural 400 
conformations of acyl-enzyme (and product) complexes formed by the reaction of SBLs with 401 
β-lactams, and of reported product/intermediate complexes formed from MBLs and β-402 
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lactams (Figure S9) (29, 61-63). Since more conformational flexibility might be anticipated 403 
once the β-lactam ring has been opened, this analysis supports the proposal that the cyclic 404 
boronates best mimic the first tetrahedral intermediate (i.e. acts as “transition-state” 405 
analogues). 406 
The cyclic boronate scaffold is thus able to potently inhibit all classes of β-lactamase 407 
by adopting an enzyme:inhibitor complex that mimics a tetrahedral intermediate in β-408 
lactam hydrolysis. With further optimisation cyclic boronates could form a new family of 409 
clinically useful β-lactamase, and maybe other hydrolytic enzyme, inhibitors. In addition to 410 
their inhibitory properties the cyclic boronates also provide important structural and 411 
mechanistic insights into the nature of β-lactamase:β-lactam complexes allowing us to build 412 
a more detailed picture of more transient species that have yet to be structurally 413 
characterised. 414 
With the first cyclic boronate drug, tavaborole (64), approved for clinical use in the 415 
treatment of external fungal infections and further cyclic boronates in the pipeline as anti-416 
inflammatory and anti-bacterial treatments (65, 66),  the use of cyclic boronates as future 417 
drug candidates seems to be an inevitability.  The ability of these molecules to mimic 418 
tetrahedral intermediates in enzyme-catalysed hydrolysis pathways may prove to be highly 419 
useful in the inhibition of mechanistically diverse enzymes, as exhibited by the ability of 1 420 
and 2 to inhibit all classes of β-lactamase, including serine-, metallo-, or other enzymes. In 421 
addition, similar classes of compounds such as cyclic phosphonates, sulfonates, and 422 
sulfonamides have yet to be extensively explored and may prove a fruitful source of future 423 
inhibitors.   424 
 425 
 426 
 o
n
 February 24, 2017 by St Bartholom
ew's & the Royal
http://aac.asm
.org/
D
ow
nloaded from
 
19 
 
Accession Number 427 
 428 
Coordinates and structure factors have been deposited in the Protein Data Bank with 429 
accession number 5FQA. 430 
 431 
Declarations of interest 432 
 433 
The authors declare no conflict of interest. 434 
 435 
Funding Information 436 
 437 
We thank the Biotechnology and Biological Sciences Research Council (grant number 438 
BB/J014427/1) and the Medical Research Council/Canadian grant (G1100135) for funding 439 
our work. We are grateful for assistance from the MRC SWON Alliance. 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 o
n
 February 24, 2017 by St Bartholom
ew's & the Royal
http://aac.asm
.org/
D
ow
nloaded from
 
20 
 
 448 
Tables & Figures 449 
Pre-incubation TEM-1 CTX-M-15 AmpC OXA-23 OXA-48 
Inhibitor Time (min) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) 
1 0 2.6 ± 0.1 92 ± 6 68 ± 3 220 ± 1 140 ± 1 
  10 1.3 ± 0.1 13 ± 1 9.8 ± 0.3 250 ± 1 160 ± 1 
  30 1.6 ± 0.1 3.7 ± 0.1 4.5 ± 0.1 260 ± 1 170 ± 1 
  60 1.5 ± 0.1 1.7 ± 0.1 2.6 ± 0.1 270 ± 1 170 ± 1 
  360 1.7 ± 0.1 4.0 ± 0.01 2.4 ± 0.1 730 ± 2 270 ± 1 
2 0 8.1 ± 0.1 39 ± 2 270 ± 60 2000 ± 100 2000 ± 100
10 3.4 ± 0.1 7.5 ± 0.3 120 ± 10 2600 ± 100 2600 ± 200
30 2.6 ± 0.1 2.8 ± 0.1 150 ± 10 3300 ± 200 3400 ± 100 
60 2.6 ± 0.1 1.3 ± 0.1 100 ± 10 2600 ± 100 3000 ± 100 
  360 2.1 ± 0.1 6.4 ± 0.1 96 ± 1 3300 ± 200 3300 ± 200 
Sulbactam 0 860 ± 80 44 ± 1 > 2 x 105 > 2 x 105 > 2 x 105 
  10 600 ± 200 29 ± 1 42000 ± 2000 > 2 x 105 > 2 x 105 
  30 600 ± 200 28 ± 7 8600 ± 600 > 2 x 105 > 2 x 105 
  60 500 ± 200 32.0 ± 0.3 4400 ± 500 > 2 x 105 > 2 x 105 
  360 700 ± 300 16.6 ± 0.1 1000 ± 400 > 2 x 105 > 2 x 105 
Avibactam 0 19 ± 1 9.9 ± 0.2 1400 ± 400 770 ± 4 2500 ± 30 
10 3.4 ± 0.1 1.1 ± 0.1 190 ± 10 390 ± 1 810 ± 50 
30 2.2 ± 0.1 0.40 ± 0.06 200 ± 10 160 ± 2 300 ± 2 
60 2.0 ± 0.1 0.39 ± 0.01 200 ± 10 71 ± 1 150 ± 1 
  360 4.3 ± 0.1 6.4 ± 0.1 150 ± 10 13 ± 1 20 ± 1 
BLI-489 0 4.8 ± 0.2 32 ± 2 210 ± 20 5.6 ± 0.1 14 ± 1 
  10 2.0 ± 0.1 6.9 ± 0.2 30 ± 1 5.6 ± 0.1 15 ± 1 
  30 1.7 ± 0.2 2.2 ± 0.1 12.0 ± 0.4 6.2 ± 0.1 16 ± 1 
  60 1.7 ± 0.1 0.94 ± 0.03 5.6 ± 0.1 8.6 ± 0.1 22 ± 1 
  360 1.9 ± 0.1 8.0 ± 0.1 1.9 ± 0.1 18 ± 1 49 ± 1 
 450 
Table 1. Time course for the inhibition of serine-β-lactamases (classes A, C and D) by 451 
boronates 1 and 2 and established inhibitors that act by formation of a stable acyl-enzyme 452 
complex, using FC5 as a substrate (30). IC50 values were taken after pre-incubation of the 453 
enzyme with the corresponding inhibitor for 0, 10, 30, 60 or 360 minutes prior to assay. 454 
IC50 values were obtained from fitting of residual activity plots using GraphPad Prism. 455 
 456 
 457 
 458 
 459 
 460 
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Pre-incubation BcII pH 7.5 BcII pH 6.5 VIM-1 pH 7.5 
Inhibitor Time (min) IC50 (μM) IC50 (μM) IC50 (μM) 
1 0 2.8 ± 0.2 3.3 ± 0.1 1 ± 1 
10 3.0 ± 0.2 3.8 ± 0.2 1 ± 1.2 
30 2.8 ± 0.3 3.5 ± 0.1 1 ± 1.5 
60 3.4 ± 0.3 3.8 ± 0.2 1.4 ± 0.3 
360 3.1 ± 0.2 3.0 ± 0.2 1.2 ± 0.3 
2 0 0.45 ± 0.02 0.27 ± 0.02 0.061 ± 0.001 
10 0.45 ± 0.02 0.20 ± 0.01 0.085 ± 0.002 
30 0.36 ± 0.02 0.20 ± 0.01 0.088 ± 0.001 
60 0.36 ± 0.01 0.20 ± 0.01 0.083 ± 0.002 
360 0.36 ± 0.03 0.23 ± 0.01 0.061 ± 0.001 
L-Captopril 0 13.7 ± 0.3 17.4 ± 0.3 1.91 ± 0.06 
10 21 ± 1 20.4 ± 0.6 2.3 ± 0.2 
30 12.5 ± 0.5 16.8 ± 0.8 2.4 ± 0.2 
60 14.6 ± 0.4 13.7 ± 0.7 2.6 ± 0.1 
360 15 ± 1 16.3 ± 0.5 2.8 ± 0.2 
(±)-Thiomandelic 0 0.30 ± 0.03 0.27 ± 0.06 0.38 ± 0.03 
Acid 10 0.39 ± 0.05 0.9 ± 0.1 0.45 ± 0.02 
30 0.33 ± 0.04 0.5 ± 0.1 0.8 ± 0.9 
60 0.5 ± 0.2 2 ± 1 1.4 ± 0.9 
360 2 ± 1 2 ± 1 2 ± 1 
 461 
Table 2. Time course for the inhibition of metallo-β-lactamases by boronates 1 and 2 and 462 
broad-spectrum thiol-based MBL inhibitors, using FC5 as a substrate (30). IC50 values were 463 
taken after pre-incubation of the enzyme with the corresponding inhibitor for 0, 10, 30, 60 464 
or 360 minutes prior to assay. IC50 values were obtained from fitting of residual activity 465 
plots using GraphPad Prism. 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
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 476 
Table 3. MIC values of selected penicillins, cephalosporins, monobactams, and carbapenems against different bacterial strains with or 477 
without cyclic boronate, 2, supplementation. MIC values in black indicate resistance and those in red suceptiobility according to current 478 
CLSI/EUCAST breakpoints. Blue values indicate where the MIC is reduced with 10 mg/L 2, but the MIC lies either outside of the susceptible 479 
range or there is no agreed breakpoint for the drug/organism combination. AMP: ampicillin; AMP/SUL: ampicillin/sulbactam; PIP: 480 
piperacillin; PIP/TAZ: piperacillin/tazobactam; TIM/CLAV: ticarcillin/clavulanate; AZT: aztreonam; FAZ: cefazolin; CRO: ceftriaxone; CAZ: 481 
ceftazidime; FEP: cefepime; ERT: ertapenem; IMI:imipenem; MEM: meropenem; DOR: doripenem. 482 
Bacterial β-Lactmases Produced  ± 2 Supplement MIC (mg/L) for β-Lactam 
 Isolate (Ambler Class)  (10 mg/L) AMP AMP/SUL PIP PIP/TAZ TIM/CLAV AZT FAZ CRO CAZ FEP ERT IMI MEM DOR 
E.coli (EC107) ST 131 CTX-M-15 (A), OXA-1 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >16 >16 >32 ≤0.25 ≤0.5 ≤0.5 ≤0.5 
    + >16 >16/8 >64 >128/4 64/2 ≤1 8 <0.5 ≤1 8 ≤0.25 ≤0.5 ≤0.5 ≤0.5 
E.coli (EC114) ST 131 TEM-1 (A), CTX-M-15 (A), OXA-1 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 ≤0.25 ≤0.5 ≤0.5 ≤0.5 
    + >16 >16/8 >64 >128/4 >64/2 ≤1 8 <0.5 ≤1 8 ≤0.25 ≤0.5 ≤0.5 ≤0.5 
E.coli (EC86) CTX-M-15 (A), CMY-4 (C), OXA-181 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >16 >16 >32 >8 >8 4 >4 
    + >16 >16/8 >64 >128/4 >64/2 8 >16 8 8 ≤4 4 4 1 2 
E.coli (EC113) ST 131 CTX-M-27 (A) - >16 8/4 >64 ≤8/4 16/2 >16 >16 >32 8 >32 ≤0.25 ≤0.5 ≤0.5 ≤0.5 
    + ≤8 ≤4/2 ≤16 ≤8/4 ≤8/2 ≤1 4 <0.5 ≤1 ≤4 ≤0.25 ≤0.5 ≤0.5 ≤0.5 
K. pneumoniae (KP15) TEM-1 (A), SHV-11 (A), KPC-2 (A) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4 
    + >16 16/8 >64 >128/4 >64/2 >16 >16 1 4 ≤4 ≤0.25 ≤0.5 1 ≤0.5 
K. pneumoniae (KP41) TEM-1 (A), SHV-1 (A), -5 (A), -11 (A), - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4 
  CTX-M-15 (A), OXA-232 (D) + >16 >16/8 >64 >128/4 64/2 >16 >16 >32 >16 32 >8 >8 >8 >4 
K. pneumoniae (KP58) SHV-11 (A), VIM-4 (B) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4 
    + >16 >16/8 >64 >128/4 >64/2 2 >16 1 2 >32 ≤0.25 2 ≤0.5 ≤0.5 
P. stuartii (PS71) TEM-1 (A), SHV-5 (A), VEB-1 (A), - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >8 
   VIM-1 (B) + >16 >16/8 >64 >128/4 >64/2 >16 4 16 >16 8 ≤0.25 >8 1 2 
P. aeruginosa (PA12) ST 111 VIM-2 (B) - >16 >16/8 >64 128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4 
    + >16 >16/8 64 128/4 >64/2 16 >16 >32 >16 >32 >8 >8 >8 >4 
A. baumannii (AB14) OXA-23 (D), OXA-51 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 4 >4 
    + >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 32 >8 >8 4 >4 
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 483 
 484 
Figure 1. Outline mechanism of cephalosporin hydrolysis by (A) serine-β-lactamases and 485 
(B) metallo-β-lactamases. The small-molecule elements of the first tetrahedral 486 
intermediate EI1 is common to both mechanisms. (C) Chemical structures of the two cyclic 487 
boronates used in this study. The structure of the proposed common tetrahedral 488 
intermediate in the serine and metallo-β-lactamase-catalysed hydrolysis of β-lactam 489 
antibiotics is shown for a cephalosporin substrate. We propose that the cyclic boronates 490 
mimic this intermediate. 491 
 492 
 493 
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 494 
Figure 2. The conformation of the bicyclic ring core of the cyclic boronates in complex with 495 
β-lactamases and PBPs is conserved and mimics the tetrahedral anionic intermediate in 496 
cephalosporin hydrolysis. (A) Active site view from a crystal structure of the CTX-M-15:1 497 
complex. Potential hydrogen bonding interactions are represented by dashed lines. (B) 498 
Overlay of energy minimised small-molecule structures of the cyclic boronate 2 and a 499 
modelled species defined by addition of a hydroxide ion onto the β-lactam carbonyl of 500 
cefalexin. Energy minimisation was carried out using the MM2 energy minimisation 501 
function in ChemBio3D Ultra. (C) Overlay of our reported (21) cyclic boronate structures in 502 
PDB entries 5FQ9 (cyan, OXA-10:1), 5FQB (magenta, BcII:2), 5FQC (yellow, VIM-2:2), 5J8X 503 
(orange, PBP-5:2) and our CTX-M-15:1 structure (green). Note that there is variation in the 504 
conformations of the side chain, but that of the fused bicyclic ring system is highly 505 
conserved in all crystal structures and is likely important for optimal binding of the cyclic 506 
boronate inhibitors. 507 
 508 
 509 
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Pre-incubation TEM-1 CTX-M-15 AmpC OXA-23 OXA-48
Inhibitor Time (min) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
1 0 2.6 ± 0.1 92 ± 6 68 ± 3 220 ± 1 140 ± 1
10 1.3 ± 0.1 13 ± 1 9.8 ± 0.3 250 ± 1 160 ± 1
30 1.6 ± 0.1 3.7 ± 0.1 4.5 ± 0.1 260 ± 1 170 ± 1
60 1.5 ± 0.1 1.7 ± 0.1 2.6 ± 0.1 270 ± 1 170 ± 1
360 1.7 ± 0.1 4.0 ± 0.01 2.4 ± 0.1 730 ± 2 270 ± 1
2 0 8.1 ± 0.1 39 ± 2 270 ± 60 2000 ± 10 2000 ± 10
10 3.4 ± 0.1 7.5 ± 0.3 120 ± 10 2600 ± 10 2600 ± 20
30 2.6 ± 0.1 2.8 ± 0.1 150 ± 10 3300 ± 20 3400 ± 10
60 2.6 ± 0.1 1.3 ± 0.1 100 ± 10 2600 ± 10 3000 ± 10
360 2.1 ± 0.1 6.4 ± 0.1 96 ± 1 3300 ± 20 3300 ± 20
Sulbactam 0 860 ± 80 44 ± 1 > 2 × 10
5
> 2 × 10
5
> 2 × 10
5
10 600 ± 200 29 ± 1 42000 ± 2000 > 2 × 10
5
> 2 × 10
5
30 600 ± 200 28 ± 7 8600 ± 600 > 2 × 10
5
> 2 × 10
5
60 500 ± 200 32.0 ± 0.3 4400 ± 500 > 2 × 10
5
> 2 × 10
5
360 700 ± 300 16.6 ± 0.1 1000 ± 400 > 2 × 10
5
> 2 × 10
5
Avibactam 0 19 ± 1 9.9 ± 0.2 1400 ± 400 770 ± 4 2500 ± 30
10 3.4 ± 0.1 1.1 ± 0.1 190 ± 10 390 ± 1 810 ± 50
30 2.2 ± 0.1 0.40 ± 0.06 200 ± 10 160 ± 2 300 ± 2
60 2.0 ± 0.1 0.39 ± 0.01 200 ± 10 71 ± 1 150 ± 1
360 4.3 ± 0.1 6.4 ± 0.1 150 ± 10 13 ± 1 20 ± 1
BLI-489 0 4.8 ± 0.2 32 ± 2 210 ± 20 5.6 ± 0.1 14 ± 1
10 2.0 ± 0.1 6.9 ± 0.2 30 ± 1 5.6 ± 0.1 15 ± 1
30 1.7 ± 0.2 2.2 ± 0.1 12.0 ± 0.4 6.2 ± 0.1 16 ± 1
60 1.7 ± 0.1 0.94 ± 0.03 5.6 ± 0.1 8.6 ± 0.1 22 ± 1
360 1.9 ± 0.1 8.0 ± 0.1 1.9 ± 0.1 18 ± 1 49 ± 1
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Pre-incubation BcII pH 7.5 BcII pH 6.5 VIM-1 pH 7.5
Inhibitor Time (min) IC50 (mM) IC50 (mM) IC50 (mM)
1 0 2.8 ± 0.2 3.3 ± 0.1 1 ± 1
10 3.0 ± 0.2 3.8 ± 0.2 1 ± 1.2
30 2.8 ± 0.3 3.5 ± 0.1 1 ± 1.5
60 3.4 ± 0.3 3.8 ± 0.2 1.4 ± 0.3
360 3.1 ± 0.2 3.0 ± 0.2 1.2 ± 0.3
2 0 0.45 ± 0.02 0.27 ± 0.02 0.061 ± 0.001
10 0.45 ± 0.02 0.20 ± 0.01 0.085 ± 0.002
30 0.36 ± 0.02 0.20 ± 0.01 0.088 ± 0.001
60 0.36 ± 0.01 0.20 ± 0.01 0.083 ± 0.002
360 0.36 ± 0.03 0.23 ± 0.01 0.061 ± 0.001
L-Captopril 0 13.7 ± 0.3 17.4 ± 0.3 1.91 ± 0.06
10 21 ± 1 20.4 ± 0.6 2.3 ± 0.2
30 12.5 ± 0.5 16.8 ± 0.8 2.4 ± 0.2
60 14.6 ± 0.4 13.7 ± 0.7 2.6 ± 0.1
360 15 ± 1 16.3 ± 0.5 2.8 ± 0.2
(±)-TMA 0 0.30 ± 0.03 0.27 ± 0.06 0.38 ± 0.03
10 0.39 ± 0.05 0.9 ± 0.1 0.45 ± 0.02
30 0.33 ± 0.04 0.5 ± 0.1 0.8 ± 0.9
60 0.5 ± 0.2 2 ± 1 1.4 ± 0.9
360 2 ± 1 2 ± 1 2 ± 1
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Bacterial b-Lactmases Produced ± 2 Supplement
 Isolate (Ambler Class)  (10 mg/L) AMP AMP/SUL PIP PIP/TAZ TIM/CLAV AZT FAZ CRO CAZ FEP ERT IMI MEM DOR
E.coli (EC107) ST 131 CTX-M-15 (A), OXA-1 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >16 >16 >32 ≤Ϭ.Ϯϱ ≤Ϭ.ϱ ≤Ϭ.ϱ ≤Ϭ.ϱ
+ >16 >16/8 >64 >128/4 64/2 ≤ϭ 8 <0.5 ≤ϭ 8 ≤Ϭ.Ϯϱ ≤Ϭ.ϱ ≤Ϭ.ϱ ≤Ϭ.ϱ
E.coli (EC114) ST 131 TEM-1 (A), CTX-M-15 (A), OXA-1 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 ≤Ϭ.Ϯϱ ≤Ϭ.ϱ ≤Ϭ.ϱ ≤Ϭ.ϱ
+ >16 >16/8 >64 >128/4 >64/2 ≤ϭ 8 <0.5 ≤ϭ 8 ≤Ϭ.Ϯϱ ≤Ϭ.ϱ ≤Ϭ.ϱ ≤Ϭ.ϱ
E.coli (EC86) CTX-M-15 (A), CMY-4 (C), OXA-181 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >16 >16 >32 >8 >8 4 >4
+ >16 >16/8 >64 >128/4 >64/2 8 >16 8 8 ≤ϰ 4 4 1 2
E.coli (EC113) ST 131 CTX-M-27 (A) - >16 08-Apr >64 ≤8/ϰ 16-Feb >16 >16 >32 8 >32 ≤Ϭ.Ϯϱ ≤Ϭ.ϱ ≤Ϭ.ϱ ≤Ϭ.ϱ
+ ≤8 ≤ϰ/Ϯ ≤ϭϲ ≤8/ϰ ≤8/Ϯ ≤ϭ 4 <0.5 ≤ϭ ≤ϰ ≤Ϭ.Ϯϱ ≤Ϭ.ϱ ≤Ϭ.ϱ ≤Ϭ.ϱ
K. pneumoniae (KP15) TEM-1 (A), SHV-11 (A), KPC-2 (A) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4
+ >16 16-Aug >64 >128/4 >64/2 >16 >16 1 4 ≤ϰ ≤Ϭ.Ϯϱ ≤Ϭ.ϱ 1 ≤Ϭ.ϱ
K. pneumoniae (KP41) TEM-1 (A), SHV-1 (A), -5 (A), -11 (A), - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4
CTX-M-15 (A), OXA-232 (D) + >16 >16/8 >64 >128/4 64/2 >16 >16 >32 >16 32 >8 >8 >8 >4
K. pneumoniae (KP58) SHV-11 (A), VIM-4 (B) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4
+ >16 >16/8 >64 >128/4 >64/2 2 >16 1 2 >32 ≤Ϭ.Ϯϱ 2 ≤Ϭ.ϱ ≤Ϭ.ϱ
P. stuartii  (PS71) TEM-1 (A), SHV-5 (A), VEB-1 (A), - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >8
 VIM-1 (B) + >16 >16/8 >64 >128/4 >64/2 >16 4 16 >16 8 ≤Ϭ.Ϯϱ >8 1 2
P. aeruginosa (PA12) ST 111 VIM-2 (B) - >16 >16/8 >64 128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 >8 >4
+ >16 >16/8 64 128/4 >64/2 16 >16 >32 >16 >32 >8 >8 >8 >4
A. baumannii (AB14) OXA-23 (D), OXA-51 (D) - >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 >32 >8 >8 4 >4
+ >16 >16/8 >64 >128/4 >64/2 >16 >16 >32 >16 32 >8 >8 4 >4
MIC (mg/L) for b-Lactam
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